Please assess the completion status of the following clinical trial:

Trial Title: Octaplas Adult TTP Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patient is a male or female at least 18 years of age or older.~2. Patient has a diagnosis of TTP or suspicion of TTP that is planned on being treated with TPE within 3 days of study entry.~3. Patient has thrombocytopenia (platelets \< 100 x 10P9P/L).~4. Patient is willing to give voluntary written informed consent before any study-related procedure is to be performed that is not part of standard medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.~Exclusion Criteria:~1. Patient has a history of severe hypersensitivity reaction to plasma-derived products or to FFP.~2. Patient has an already known IgA deficiency with documented antibodies against IgA.~3. Patient is currently participating in an interventional clinical study or has participated during the past 1 month prior to study inclusion.~4. Patient has severe deficiencies of Protein S.~5. Patient received more than 1 treatment of plasma exchange or plasma infusion for current episode of TTP prior to randomization.~6. Patient is currently taking ACE-inhibitors; in case patient is under ACE-inhibitor treatment a wash-out period of at least 24 hours has to elapse prior the first plasma infusion.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Octaplas (Type: None): Patients receiving Octaplas for the treatment of Thrombotic Thrombocytopenic Purpura (TTP) undergoing therapeutic plasma exchange (TPE) procedures
- standard plasma products (Type: None): Patients receiving standard plasma products (e.g., FFP, etc) for the treatment of Thrombotic Thrombocytopenic Purpura (TTP) undergoing therapeutic plasma exchange (TPE) procedures

Based on this trial design, predict the completion outcome and termination type (if applicable).